https://doi.org/10.1016/s2468-1253(22)00005-x
H
Hajir Ibraheim
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
1.1K
Citations
16
h-index
19
i10-index
Hajir Ibraheim is an academic researcher from Royal Marsden Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Microscopic Colitis & Inflammatory Bowel Disease. The author has an h-index of 16, co-authored 64 publications.
ORCID: 0000-0002-0563-2547Papers by this author
worksCOVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
2022 · The Lancet. Gastroenterology & hepatology · 147 citations
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
2022 · The Lancet. Gastroenterology & hepatology · 64 citations
https://doi.org/10.1016/s2468-1253(22)00274-6
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
2023 · EBioMedicine · 54 citations
https://doi.org/10.1016/j.ebiom.2022.104430
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
2022 · Gastroenterology · 14 citations
https://doi.org/10.1053/j.gastro.2022.10.010
Tu1734 BLOCKADE OF IL-27, BUT NOT IL-1B, ATTENUATES IMMUNE CHECKPOINT INHIBITOR COLITIS
2024 · Gastroenterology · 0 citations
https://doi.org/10.1016/s0016-5085(24)03671-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat